NVIV.Q Stock Overview
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
InVivo Therapeutics Holdings Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$1.64 |
| 52 Week Low | US$0.15 |
| Beta | 0.52 |
| 1 Month Change | 38.46% |
| 3 Month Change | -44.00% |
| 1 Year Change | -73.33% |
| 3 Year Change | -98.22% |
| 5 Year Change | -99.97% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
InVivo Therapeutics dips 24% on $9M direct and private placement offerings
Oct 07We're Not Very Worried About InVivo Therapeutics Holdings' (NASDAQ:NVIV) Cash Burn Rate
Aug 26
Is InVivo Therapeutics Holdings (NASDAQ:NVIV) In A Good Position To Invest In Growth?
May 05Will InVivo Therapeutics Holdings (NASDAQ:NVIV) Spend Its Cash Wisely?
Jan 18Shareholder Returns
| NVIV.Q | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.5% | 1.8% | 1.2% |
| 1Y | -73.3% | -0.5% | 24.9% |
Price Volatility
| NVIV.Q volatility | |
|---|---|
| NVIV.Q Average Weekly Movement | 48.9% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Volatility Over Time: NVIV.Q's weekly volatility has increased from 26% to 49% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 6 | Rich Toselli | www.invivotherapeutics.com |
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment.
InVivo Therapeutics Holdings Corp. Fundamentals Summary
| NVIV.Q fundamental statistics | |
|---|---|
| Market cap | US$1.12m |
| Earnings (TTM) | -US$9.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs NVIV.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVIV.Q income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.33m |
| Earnings | -US$9.33m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NVIV.Q perform over the long term?
See historical performance and comparison